Guard Therapeutics International AB (publ) (GUARD.ST)
SEK 16.7
(0.6%)
SEK 16.7
(0.6%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -1486.00 SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | -100.0% |
| 2019 | 527 Thousand SEK | 140.98% |
| 2018 | -1.28 Million SEK | -39.03% |
| 2017 | -925 Thousand SEK | 29.01% |
| 2016 | -1.3 Million SEK | 30.77% |
| 2015 | -1.88 Million SEK | -12446.67% |
| 2014 | -15 Thousand SEK | -1650165016501750.2% |
| 2013 | - SEK | 100.0% |
| 2012 | -991.00 SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - SEK | 100.0% |
| 2024 Q1 | -1.53 Million SEK | -103399.26% |
| 2023 Q1 | -2093.00 SEK | 0.0% |
| 2023 Q4 | -1486.00 SEK | 6.07% |
| 2023 FY | -1486.00 SEK | 0.0% |
| 2023 Q3 | -1582.00 SEK | 19.57% |
| 2023 Q2 | -1967.00 SEK | 6.02% |
| 2022 Q3 | - SEK | 100.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q2 | -812 Thousand SEK | 43.65% |
| 2022 Q4 | - SEK | 0.0% |
| 2022 Q1 | -1.44 Million SEK | -54.78% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q1 | -938 Thousand SEK | 0.0% |
| 2021 Q4 | -931 Thousand SEK | -396.5% |
| 2021 Q3 | 314 Thousand SEK | 174.58% |
| 2021 Q2 | -421 Thousand SEK | 55.12% |
| 2020 Q4 | - SEK | 0.0% |
| 2020 FY | - SEK | -100.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 FY | 527 Thousand SEK | 140.98% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | -1.28 Million SEK | -39.03% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | -925 Thousand SEK | 29.01% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | -1.3 Million SEK | 30.77% |
| 2016 Q4 | - SEK | 0.0% |
| 2015 FY | -1.88 Million SEK | -12446.67% |
| 2015 Q2 | - SEK | 100.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 100.0% |
| 2014 Q1 | -10 Thousand SEK | -1100110011001200.2% |
| 2014 Q4 | -15 Thousand SEK | 0.0% |
| 2014 FY | -15 Thousand SEK | -1650165016501750.2% |
| 2014 Q3 | - SEK | 100.0% |
| 2014 Q2 | -3000.00 SEK | 70.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 100.0% |
| 2013 Q3 | -3000.00 SEK | -164835164835264.84% |
| 2013 Q4 | - SEK | 100.0% |
| 2013 FY | - SEK | 100.0% |
| 2012 FY | -991.00 SEK | 0.0% |
| 2012 Q4 | -991.00 SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| NextCell Pharma AB | 545.23 Thousand SEK | 100.273% |
| Biovica International AB (publ) | 2.19 Million SEK | 100.068% |
| Abliva AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 40.56% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Alligator Bioscience AB (publ) | 2.00 SEK | 74400.0% |
| BioInvent International AB (publ) | 11.84 Million SEK | 100.013% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 100.016% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 100.007% |
| Cantargia AB (publ) | - SEK | Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 100.037% |
| CombiGene AB (publ) | -1.79 Million SEK | 99.917% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 100.212% |
| Fluicell AB (publ) | 3.15 Million SEK | 100.047% |
| Genovis AB (publ.) | 14.9 Million SEK | 100.01% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 100.015% |
| Mendus AB (publ) | - SEK | Infinity% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | - SEK | Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Saniona AB (publ) | 1.00 SEK | 148700.0% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 148700.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 99.979% |
| Xintela AB (publ) | 398 Thousand SEK | 100.373% |
| Amniotics AB (publ) | 534 Thousand SEK | 100.278% |
| Corline Biomedical AB | -3.85 Million SEK | 99.961% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 99.668% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 248.6% |
| Intervacc AB (publ) | 10.48 Million SEK | 100.014% |
| Kancera AB (publ) | -1950.00 SEK | 23.795% |
| Lipum AB (publ) | - SEK | Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 99.909% |
| Nanologica AB (publ) | 2.97 Million SEK | 100.05% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 100.001% |
| AcouSort AB (publ) | 2.08 Million SEK | 100.071% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 100.006% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 100.004% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 100.003% |
| Simris Alg AB (publ) | 1.09 Million SEK | 100.136% |
| Ziccum AB (publ) | -4.18 Million SEK | 99.965% |
| SynAct Pharma AB | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 99.828% |
| Camurus AB (publ) | 100.95 Million SEK | 100.001% |
| 2cureX AB (publ) | -1000.00 SEK | -48.6% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 99.537% |
| I-Tech AB | 4.28 Million SEK | 100.035% |
| Cyxone AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 99.97% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | -3.27 Million SEK | 99.955% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 100.061% |
| Pila Pharma AB (publ) | 1.00 SEK | 148700.0% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 100.145% |